Evidence map›Paper›PMID 40518107›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2025

Prognostic value of

Ardel J Romero Pabón, Olivier F Clerc, Sarah A M Cuddy, Shilpa Vijayakumar, Zhou Lan, Hanna K Gaggin, Marcelo F Di Carli, Rodney H Falk, Sharmila Dorbala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ardel J Romero PabónCardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Olivier F ClercCardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sarah A M CuddyCardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Shilpa VijayakumarCardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Zhou LanDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Center for Clinical Investigation, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hanna K GagginCardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Marcelo F Di CarliDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rodney H FalkCardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sharmila DorbalaCardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: sdorbala@bwh.harvard.edu.

Funding

Noninvasive Cardiovascular Imaging Research Training ProgramT32HL094301 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Marcelo F DI CARLI · 2010 to 2026
$7.8M
Interplay of Myocardial Fibrosis and Cardiac TTR Amyloid in Age Related Cardiac Remodeling in MESA-Multi-Ethnic Study of AtherosclerosisR01HL159987 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DORBALA, SHARMILA, LIMA, JOAO A C · 2022 to 2025
$5.6M
Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late LifeR01HL150342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, SHAH, AMIL M · 2020 to 2023
$4.1M
Molecular Imaging of Primary Amyloid CardiomyopathyR01HL130563 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, FALK, RODNEY H · 2016 to 2019
$3.3M
Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac AmyloidosisK23HL166686 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Sarah AM Cuddy · 2023 to 2026
$756k
Mentoring Patient Oriented Research in Innovative Imaging and High-dimensional Data Approaches to Improve Outcomes in Cardiac AmyloidosisK24HL157648 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA · 2021 to 2025
$612k
Elucidating Mechanisms of Cardiac Dysfunction Using Imaging and ProteomicsK99HL175107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CLERC, OLIVIER FLORIAN · 2024 to 2025
$214k
American Heart Association-American Stroke Association 23CDA857664NHLBI NIH HHS K23 HL166686NHLBI NIH HHS K24 HL157648NHLBI NIH HHS K99 HL175107NHLBI NIH HHS R01 HL130563NHLBI NIH HHS R01 HL150342NHLBI NIH HHS R01 HL159987NHLBI NIH HHS T32 HL094301
6 · The paper itself

Abstract

backgroundThe aim of our study was to evaluate the prognostic value of amyloid burden estimated by technetium-pyrophosphate single-photon emission computed tomography (

methodsOur retrospective cohort study included 344 ATTR-CM participants receiving TTR stabilization therapy.

resultsOf the 344 participants (median age: 80 years), 88% were men and 98% had a

conclusionsIn patients with ATTR-CM receiving TTR stabilization therapy, organ dysfunctions evidenced by NAC stage and NYHA class, but not by amyloid burden on

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesTechnetium Tc 99m PyrophosphateTomography, Emission-Computed, Single-PhotonAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRadiopharmaceuticalsRetrospective StudiesRadiopharmaceuticalsTechnetium Tc 99m PyrophosphateATTR-CMPrognosisSPECT/CTTransthyretin amyloid cardiomyopathyTTR stabilization therapy

Identifiers

PMID40518107
PMCPMC12320195

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.